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Toll-like receptors (TLRs) are a family of pat-
tern recognition receptors that have evolved to 
detect invading microorganisms and link recog-
nition to induction of antimicrobial defense. In 
mammals, TLR9, TLR7, and TLR3 recognize 
nonmethylated  CpG  motifs  in  DNA,  single-
stranded  RNA,  and  double-stranded  RNA, 
respectively. These ligands are conceptually dis-
tinct among TLRs because they exist within 
the host as well as within potential pathogens. 
Thus, although nucleic acid recognition enables 
detection of viral infection, this strategy can also 
result in self-recognition. Indeed, recognition 
of self–nucleic acids by TLR7 and TLR9 can 
contribute to the pathology of autoimmune 
diseases such as rheumatoid arthritis and sys-
temic lupus erythematosus (Krieg and Vollmer, 
2007). These observations indicate that, unlike 
other TLR family members, the ability to dis-
tinguish between self- and nonself–nucleic acids 
is not based simply on molecular recognition. 
Instead, the capacity to bind nucleic acids has 
been  coupled  to  a  unique  localization  and 
regulatory program, which appears to play an 
important role in limiting the potential for self–
nucleic acid recognition (Barton et al., 2006). 
TLR3, TLR7, and TLR9 localize to and ex-
clusively signal from endolysosomal compart-
ments. Unlike the surface-localized TLRs, these 
TLRs have an ER-resident pool, and exit from 
the ER is controlled by Unc93b1 (Tabeta et al., 
2006; Ewald et al., 2008; Kim et al., 2008). 
Perhaps most strikingly, recent studies have 
demonstrated that TLR9 is processed in en-
dolysosomal compartments by resident prote-
ases and this processing is required to generate a 
functional receptor (Ewald et al., 2008; Park 
et al., 2008; Sepulveda et al., 2009).
Although  there  is  consensus  that  acid- 
dependent proteases are required for TLR9 pro-
cessing, the specific proteases involved remain 
somewhat controversial (Ewald et al., 2008; Park 
et al., 2008; Sepulveda et al., 2009). Cathepsins 
are likely candidates, as members of this prote-
ase family are activated in a pH-dependent 
manner throughout endosome maturation and 
play a well established role in peptide processing 
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Toll-like receptor (TLR) 9 requires proteolytic processing in the endolysosome to initiate 
signaling in response to DNA. However, recent studies conflict as to which proteases are 
required for receptor cleavage. We show that TLR9 proteolysis is a multistep process. The 
first step removes the majority of the ectodomain and can be performed by asparagine 
endopeptidase (AEP) or cathepsin family members. This initial cleavage event is followed by 
a trimming event that is solely cathepsin mediated and required for optimal receptor 
signaling. This dual requirement for AEP and cathepsins is observed in all cell types that we 
have analyzed, including mouse macrophages and dendritic cells. In addition, we show that 
TLR7 and TLR3 are processed in an analogous manner. These results define the core proteo-
lytic steps required for TLR9 function and suggest that receptor proteolysis may represent a 
general regulatory strategy for all TLRs involved in nucleic acid recognition.
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Park  et  al.,  2008). 
The  question  of 
whether TLR3 is cleaved has not been addressed.
To resolve these outstanding questions, we have exam-
ined the role of different proteases in receptor processing in 
macrophages, DCs, and fibroblasts. We find that receptor 
cleavage occurs through a multistep process. The first step 
can be mediated either by AEP or by multiple members of 
the cathepsin family of proteases. This first processing event 
is followed by a second, exclusively cathepsin–mediated,   
N-terminal trimming which is also required for optimal re-
ceptor function. These requirements appear to be conserved 
across all cell types analyzed. Importantly, we also show that 
TLR7 and TLR3 are processed in a similar manner, implying 
that receptor proteolysis is a conserved mode of regulating 
all nucleic acid–sensing TLRs.
RESULTS AND DISCUSSION
Cathepsins mediate secondary trimming of cleaved TLR9
To address the question of which proteases are required for 
TLR9 processing, we performed a detailed analysis of the 
effects of various protease inhibitors on RAW cells (a macro-
phage cell line) stably transduced with a C-terminally HA-
tagged version of TLR9 (TLR9-RAW). Treatment with 
broad-spectrum serine (pepstatin A) or cysteine (leupeptin) 
inhibitors or with a highly selective aza-peptidyl-asparagine 
epoxide inhibitor of AEP (or legumain inhibitor 1 [LI-1]; Lee 
and Bogyo, 2010) did not block TLR9 cleavage (Fig. 1 A). 
Upon treatment with cathepsin inhibitors E64d (also known 
as EST; Fig. 1 B) or z-FA-FMK (Fig. 2 A), the majority of 
the ectodomain was still removed; however, the resulting 
for MHCII loading in macrophage and DCs (Rudensky and 
Beers, 2006). Before the discovery of TLR9 proteolysis, ctsB 
and ctsL, as well as ctsK, were implicated in TLR9 signaling 
in studies using Baf/3 cells and an antigen-induced arthritis 
model, respectively (Asagiri et al., 2008; Matsumoto et al., 
2008). However, the use of knockout mice has ruled out ctsB, 
ctsL, ctsK, ctsS, and ctsF as individual proteases required for 
TLR9 processing in macrophages (Ewald et al., 2008; Park 
et al., 2008). One study noted that combined treatment with 
ctsS and ctsL inhibitors resulted in a larger nonfunctional form 
of cleaved TLR9, dubbed the “pre–C-terminal fragment,” 
suggesting that certain cathepsin family members may play a 
more prevalent role in TLR9 processing than others (Park 
et al., 2008). However, a recent paper by Sepulveda et al. 
(2009) has shown that asparagine endopeptidase (AEP; also 
known as mammalian legumain), a cysteine protease with a 
strict substrate specificity for asparagine residues, is required 
for TLR9 processing and signaling in DCs. Under resting 
conditions, AEP-deficient cells were unable to cleave phago-
somal TLR9 and signaling was greatly impaired.
Based on these results, it is unclear how all of these prote-
ases contribute to TLR9 processing and signaling events. TLR9 
processing could be achieved by the functionally redundant 
role of different proteases depending on cell type, or several 
proteases could perform complementary, nonoverlapping, or 
partially overlapping roles in the processing of TLR9. Fur-
thermore, the studies discussed in the previous paragraphs 
have largely focused on TLR9 as a representative of the 
nucleic acid–sensing TLRs. Recent results conflict as to whether 
TLR7, which also contributes to autoimmunity, is subject to 
the same proteolytic regulation as TLR9 (Ewald et al., 2008; 
Figure 1.  TLR9 cleavage is a multistep 
event. (A and B) TLR9 cleavage in TLR9-RAW 
cells was monitored by pulse-chase analysis 
in the presence of the indicated protease 
inhibitors or DMSO (as vehicle control). The 
full-length form of TLR9 (FL TLR9) and two 
cleavage products (mature cleaved TLR9 and 
untrimmed cleaved TLR9) are labeled. The pool 
of full-length TLR9 that has exited the ER but 
has not yet been cleaved is also labeled  
(hmTLR9). (C) Analysis of TNF production by 
intracellular cytokine staining. RAW cells were 
pretreated for 12 h with the indicated prote-
ase inhibitors (broad spectrum cathepsin in-
hibitors [z-FA-FMK or E64d], AEP inhibitor 
[LI-1], a combination of ctsS inhibitor [ctsS I.], 
ctsL inhibitor [ctsL I.], and ctsB inhibitor [ctsB I.], 
or vehicle control [DMSO]) followed by 4 h of 
stimulation with the indicated concentrations 
of CpG or LPS. Graph represents the ratio of 
the percentage of TNF-expressing cells in 
stimulated and unstimulated conditions. Rep-
resentative FACS plots are shown in Fig. S2. 
(D) Schematic depicting the unique require-
ment of cathepsins for trimming TLR9 once 
the majority of the ectodomain has been re-
moved, generating the mature form of the 
cleaved receptor. All data are representative of 
at least five experiments.JEM VOL. 208, April 11, 2011  645
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cells suggests that the initial proteolytic event can occur at 
multiple sites within TLR9.
In previous work, we established that full-length TLR9 
that has exited the ER is modified so that it appears to be 
slightly larger than the majority of the full-length protein (re-
ferred to as high-migrating [hm] TLR9; Ewald et al., 2008). 
Treatment with bafilomycinA1, an inhibitor of the vacuolar 
ATPase which blocks acid-dependent protease activity, pre-
vents receptor proteolysis and results in the accumulation of 
hmTLR9 (Fig. 1 A; Ewald et al., 2008). It is of note that 
treatment with E64d (Fig. 1 B) or z-FA-FMK (Fig. 2 A) 
resulted in a moderate accumulation of hmTLR9, although 
C-terminal product was slightly larger than that observed 
in untreated cells (Fig. 1 B). To better resolve this size dif-
ference, we used the endoglycosidase PNGase to remove 
N-linked  sugars  from  the  C-terminal  TLR9  fragment. 
Deglycosylation revealed several distinct bands within the 
C-terminal fragment which otherwise appear as a single dif-
fuse band (Fig. S1). Moreover, in the presence of z-FA-FMK 
these deglycosylated bands shifted to a higher molecular mass. 
These data are consistent with the interpretation that cathep-
sins can trim additional fragments from the TLR9 C terminus 
after the initial cleavage event (Park et al., 2008). Further-
more, the presence of multiple bands in z-FA-FMK–treated 
Figure 2.  AEP and cathepsins account for cleavage of the TLR9 ectodomain. (A and B) TLR9 cleavage in Unc93b1-TLR9-MEF cells or TLR9-RAW 
cells was monitored by pulse-chase analysis in the presence of indicated protease inhibitors or DMSO (as vehicle control). (C) Efficiency of protease 
inhibition of live cells was determined by probing cell lysates with tagged protease inhibitor probes. RAW cells were pretreated with z-FA-FMK (z-FA), 
LI-1, or DMSO. Cell lysates were then probed with the cathepsin probe DCG-04-biotin (top) or the AEP probe BODIPY-LI-1 (bottom) and visualized as 
described in Materials and methods. Bands corresponding to individual proteases are indicated on the right. (D) Analysis of TNF production by RAW 
cells using intracellular cytokine staining as described in Fig. 1. Representative FACS plots are shown in Fig. S3. All data are representative of at least 
three experiments.646 Processing of nucleic acid–sensing TLRs | Ewald et al.
novel protease (or proteases) or by the redundant activities of 
multiple  proteases  belonging  to  different  families  (families 
that were not cross-inhibited by the broad spectrum inhibi-
tors we tested). To test the first possibility, we conducted a 
protease  inhibitor  screen  using  a  library  of  1,500  com-
pounds designed to target cysteine and serine proteases with 
the goal of identifying compounds that blocked TLR9 re-
sponses  to  CpG.  Although  this  approach  revealed  several 
novel compounds that were able to block TLR9 signaling, 
subsequent analysis of TLR9 processing indicated that all of 
these compounds blocked cathepsin-mediated trimming rather 
than the primary cleavage event (unpublished data).
Based on these results, we decided to examine the possibil-
ity that the initial processing event was a result of the redun-
dant or overlapping activities of multiple proteases belonging 
to different families. As a starting point, we opted to use 
mouse embryonic fibroblasts (MEFs) because these cells are less 
proteolytically complex than macrophages but can still cleave 
TLR9 efficiently once they have been transduced with 
Unc93b1, an integral membrane protein required for ER   
export and signaling of nucleic acid–sensing TLRs (Tabeta et al., 
2006; Brinkmann et al., 2007; Ewald et al., 2008). Because ca-
thepsins had already been implicated in TLR9 processing, we 
began by treating MEFs stably expressing TLR9 and Unc93b1 
(Unc93b1-TLR9-MEF) with cathepsin inhibitors together 
with additional inhibitors. Analysis of TLR9 cleavage by pulse-
chase revealed that the combination of LI-1 and z-FA-FMK 
was sufficient to block TLR9 cleavage to an extent equivalent 
to treatment with bafilomycin A1 (Fig. 2 A compared with 
Fig. 1 A). In contrast, combining z-FA-FMK with pepstatin A 
and leupeptin did not block the initial cleavage event but only 
resulted in secondary trimming, similar to treatment with 
cathepsin inhibitors alone. As observed in TLR9-RAW cells, 
TLR9 cleavage was unaffected in Unc93b1-TLR9-MEF cells 
treated with LI-1 alone (Fig. 2 B). Importantly, the combina-
tion of z-FA-FMK and LI-1 was also sufficient to entirely block 
receptor proteolysis in TLR9-RAW cells, indicating that simi-
lar proteolytic events occur in both cell types (Fig. 2 B).
not to the degree observed upon bafilomycinA1 treatment 
(Fig. 1 B; Ewald et al., 2008). The partial stabilization of 
hmTLR9 and formation of the untrimmed C-terminal fragments 
in the presence of cathepsin inhibitors are consistent with 
previous work suggesting that TLR9 processing may involve 
multiple sequential steps (Park et al., 2008). However, our 
results disagree with this work in one important respect: we do 
not observe that TLR9 processing is mediated entirely by ca-
thepsins. Rather, the first step, performed by an unidentified 
protease (or proteases), results in removal of the majority of 
the ectodomain followed by secondary trimming of the exposed 
N termini, which is entirely cathepsin dependent (Fig. 1 D).
To determine whether cathepsin-mediated trimming has 
functional relevance for TLR9, RAW cells were treated with 
inhibitors before stimulation and TNF production was mea-
sured by intracellular cytokine staining. At lower concentrations 
of ligand, the TLR9 response to CpG could be largely blocked 
by pretreatment with E64d and z-FA-FMK or a combination 
of three individual cathepsin inhibitors; however, this inhibition 
was never entirely complete (Fig.1 C and Fig. S2). The increase 
of the amount of ligand to 1 µM or greater was able to over-
come treatment with cathepsin inhibitors, perhaps explaining 
some of the discrepancy between previous studies, which con-
flict as to whether inhibition of cathepsins is sufficient to block 
TLR9 signaling (Ewald et al., 2008; Park et al., 2008). In previ-
ous studies, we and others have shown that individual cathepsin 
inhibitors are not sufficient to block TLR9 proteolysis (Ewald 
et al., 2008; Park et al., 2008), although one group has reported 
that combined inhibition of ctsS and ctsL appears to have a sig-
nificant effect on trimming (Park et al., 2008). Collectively, we 
interpret these data to indicate that TLR9 trimming is a result 
of the redundant activities of multiple cathepsins.
AEP and cathepsins can both perform the first cleavage 
event in TLR9 processing
Based on the finding that broad-spectrum inhibitors failed to 
block the primary TLR9 cleavage event, we hypothesized 
that this first step in TLR9 cleavage was mediated either by a 
Figure 3.  In the absence of AEP, TLR9 cleavage in macrophages is entirely cathepsin dependent. (A) Quantitative RT-PCR analysis of AEP tran-
script levels in TLR9-RAW cells transduced with an shRNA construct targeting AEP (AEP-shRNA) or vector control. AEP levels were normalized to rps17 
expression. Error bars represent standard deviation. * represents P ≤ 0.001 based on Student’s t test. (B) TLR9 cleavage in the cells described in A as ana-
lyzed by pulse-chase analysis in the presence of indicated protease inhibitors (z-FA-FMK; LI-1) or DMSO (as vehicle control). All data are representative of 
two experiments. (C) Schematic illustrating the overlapping roles of AEP and cathepsins in the initial removal of the TLR9 ectodomain.JEM VOL. 208, April 11, 2011  647
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appearance of cleaved TLR9 and allow hmTLR9 to accumu-
late (Fig. 3 B). In contrast, z-FA-FMK treatment only pre-
vented receptor trimming in the vector-transduced control 
cells (Fig. 3 B, vec.-TLR9-RAW). We interpret these results 
to indicate that cathepsins are sufficient to carry out both 
TLR9 processing steps in the absence of AEP (Fig. 3 C).
Cathepsin activity is required for optimal TLR9 processing 
and function in DCs
A recent paper from Sepulveda et al. (2009) has described a 
significant defect in TLR9 processing and signaling in AEP-
deficient DCs. This role for AEP in TLR9 function was only 
observed in DCs. Although our results with macrophages and 
fibroblasts suggest that cathepsins can mediate TLR9 process-
ing in the absence of AEP, it is possible that the proteases re-
quired for TLR9 processing in DCs are distinct from those in 
To ensure that our protease inhibitor conditions were 
efficient as well as specific, we used activity-based probes to 
detect active proteases in treated or untreated cells. Lysates of 
RAW cells pretreated with z-FA-FMK or LI-1 were incubated 
with  activity-based  probes  DCG-04  (a  biotinylated  probe 
built on the E64d structure) or BODIPY-conjugated LI-1 
(BODIPY-LI-1) to detect any cathepsins or AEP that remained 
unblocked after treatment (Greenbaum et al., 2000; Lee and 
Bogyo, 2010). Importantly, pretreatment with z-FA-FMK 
completely blocked cathepsin activity (Fig. 2 C, top), and 
pretreatment with LI-1 completely blocked AEP activity 
(Fig. 2 C, bottom, LI-1 lane). Furthermore, this assay revealed 
that cells treated with cathepsin inhibitors maintained AEP 
activity (Fig. 2 C, bottom, z-FA-FMK lane) and vice versa 
(Fig. 2 C, top, LI-1 lane), verifying, as previously reported, 
that these inhibitors do not cross react (Lee and Bogyo, 2010).
Consistent with the biochemical data, treatment with 
z-FA-FMK and LI-1 reduced TNF production in response 
to CpG DNA to levels comparable to unstimulated cells, 
whereas treatment with LI-1 alone had no effect on signaling 
(Fig. 2 D and Fig. S3). Notably, this effect on signaling could 
be overcome by treatment with very high concentrations of 
ligand (>5 µM; not depicted). This observation may be the 
result of low levels of residual protease activity, suboptimal 
signaling from untrimmed or unprocessed TLRs, or TLR9 
that was processed before inhibitor treatment. We have de-
termined that the cleaved form of TLR9 is extremely stable; 
pulse-chase analysis indicates it remains detectable after 12 h 
of chase (unpublished data). However, it is unlikely that the 
large concentrations of ligand required to overcome inhibitor 
treatment are physiologically relevant.
In the absence of AEP, TLR9 processing is entirely  
cathepsin dependent
The data presented thus far suggest that cathepsins and AEP 
play a functionally redundant role in the first step of TLR9 
proteolysis. In the absence of AEP activity, cathepsins can com-
pensate for the initial processing event as well as trim the 
processed receptor, resulting in the fully mature form of 
TLR9. In contrast, when cathepsin activity is blocked, the 
initial processing event is still performed by AEP; however, 
the cleaved receptor can no longer be trimmed, which results 
in a slightly larger cleaved form of the receptor and impaired 
signaling (Fig. 3 C, model).
This model predicts that in the absence of AEP, TLR9 
processing should be entirely cathepsin dependent. To test 
this possibility, we stably transduced TLR9-RAW cells with 
retroviruses encoding a short hairpin RNA (shRNA) targeting 
AEP (AEPsh-TLR9-RAW). AEP transcript levels in AEPsh-
TLR9-RAW cells were reduced to nearly 25% of the lev-
els normally seen in vector-transduced TLR9-RAW cells 
(Fig. 3 A). Pulse-chase analysis revealed that TLR9 processing 
in AEP knockdown cells was intact, which is consistent 
with our observation that LI-1 treatment alone does not 
impair TLR9 processing (Fig. 2 B). However, treatment with 
z-FA-FMK was now sufficient to completely block the 
Figure 4.  TLR9 signaling and cleavage in DCs requires AEP and 
cathepsins. (A and B) TNF production by GM-CSF–derived DCs (A) or 
DC2.4 cells (B) was monitored by intracellular cytokine staining as de-
scribed in Fig. 1. Representative FACS plots are shown in Fig. S4. Data are 
representative of three experiments. (C) TLR9 cleavage in TLR9-DC2.4 cells 
or DC2.4 cells was monitored by pulse-chase analysis as described in  
Materials and methods. Data are representative of four experiments.  
(D) Quantitative RT-PCR analysis of AEP transcript levels in TLR9-DC2.4 
cells transduced with the AEP shRNA (AEP-shRNA) or an unrelated gene 
product (control). AEP levels were normalized to rps17 expression. Error 
bars represent standard deviation. * represents P ≤ 0.005 based on Student’s 
t test. (E) TLR9 cleavage in the cells described in D visualized by immuno-
blot after immunoprecipitation after 14 h of z-FA-FMK or DMSO treatment. 
Data in E are representative of three experiments.648 Processing of nucleic acid–sensing TLRs | Ewald et al.
support a potentially greater role for AEP in DCs than in 
other cell types. It is possible that our inability to resolve a 
dominant role for AEP in TLR9 processing is a result of our 
use of pharmacological inhibition of AEP which is unlikely 
to be as complete as a genetic deficiency in AEP (Sepulveda 
et al., 2009). However, our analysis of AEP knockdown cells 
also implicates cathepsins in TLR9 processing in DCs. This is 
consistent with the observation that AEP-independent prote-
olysis of TLR9 occurs after DC activation (Sepulveda et al., 
2009). AEP has also been shown to contribute to the process-
ing of procathepsins, so another explanation for the discrep-
ancy in protease bias for TLR9 maturation is that AEP-deficient 
cells may have reduced activity of other proteases, most notably 
cathepsins (Shirahama-Noda et al., 2003; Maehr et al., 2005). 
In any case, our analysis of signaling and receptor processing 
support a role for both cathepsins and AEP in TLR9 prote-
olysis in all cell types tested. It remains formally possible that 
certain cell types rely more heavily on subsets of these prote-
ases, especially considering reports of significantly distinct 
protease complexity between cell types (Delamarre et al., 
2005). Additional analysis of purified populations of cells may 
address this possibility.
TLR3 and TLR7 are processed and require cathepsin activity 
for optimal signaling
If receptor proteolysis represents a strategy to avoid recogni-
tion of self-nucleic acids, then one might expect nucleic acid–
sensing TLRs other than TLR9 to be similarly regulated. 
Based on our findings that cathepsins and AEP are required 
for TLR9 processing, we examined the role of these prote-
ases in the activation of TLR3 and TLR7. First, we measured 
TNF produced in response to the TLR7 ligand R848 or 
the TLR3 ligand poly(I:C) in RAW cells pretreated with 
z-FA-FMK, LI-1, or both inhibitors. Similar to our results 
with TLR9, TLR7 and TLR3 responses were impaired in cells 
treated with z-FA-FMK or z-FA-FMK combined with LI-1 
other cell types. To address this possibility, we first examined 
the effect of cathepsin and AEP inhibitors on TLR9 signaling 
in DCs derived from bone marrow with GM-CSF or in the 
DC cell line DC2.4. Similar to our experiments with macro-
phages (Fig. 2), we observed that TNF production in response 
to CpG was inhibited by z-FA-FMK (Fig. 4, A and B; and 
Fig. S4). Inhibition of AEP did result in slightly reduced 
TLR9 signaling, suggesting that AEP may play a more preva-
lent role in TLR9 processing in DCs than in macrophages 
and fibroblasts. However, TNF production was more effec-
tively blocked by z-FA-FMK than by LI-1. Combined treat-
ment with z-FA-FMK and LI-1 resulted in greater inhibition 
of TLR9 signaling compared with z-FA-FMK alone (Fig. 4, A 
and B).
To examine more directly the relative contribution of 
these proteases on TLR9 cleavage in DCs, we generated 
DC2.4  cells  stably  expressing  TLR9-HA  (TLR9-DC2.4). 
Similar to our results in macrophages and fibroblasts, z-FA-FMK 
treatment inhibited only the second proteolytic event (Fig. 4 C). 
Inhibition of AEP alone had no detectable effect on pro-
cessing. However, inhibition of AEP and cathepsins in com-
bination  blocked  processing  completely  and  resulted  in 
accumulation of the high migrating form of TLR9 (hmTLR9; 
Fig. 4 C). As a final approach, we knocked down AEP in 
TLR9-DC2.4 cells (AEPsh-TLR9-DC2.4) using the same 
shRNA as that described earlier (Fig. 4 D). The combination 
of cathepsin inhibition and AEP knockdown allowed the un-
processed  hmTLR9  band  to  accumulate  and  reduced  the 
amount of cleaved TLR9 (Fig. 4 E). TLR9 signaling corre-
lated with these biochemical data; AEP knockdown cells re-
sponded normally to CpG DNA but were more sensitive to 
cathepsin inhibitors than control cells (Fig. S5).
Collectively, these results indicate that cathepsins play a 
prominent role in TLR9 proteolysis in DCs as well as in 
macrophages. The role for AEP appears to be largely redun-
dant with cathepsins, although our signaling experiments do 
Figure 5.  TLR7 and TLR3 are regulated by receptor proteolysis. (A) TNF production by RAW cells in response to TLR9, TLR3, and TLR7 ligands was 
measured by intracellular cytokine staining as described in Fig. 1. Representative FACS plots are shown in Fig. S6. (B and C) TLR7 (B) and TLR3 (C) are 
cleaved after trafficking through the Golgi. TLR7-RAW (B) or TLR3-RAW (C) cell immunoprecipitates were treated with Endo H (E), PNGase (P), or no  
enzyme control () to assess glycosylation status by anti-HA Western blotting. The bottom panel in C is a shorter exposure of the TLR3 cleaved product. 
All data are representative of three experiments.JEM VOL. 208, April 11, 2011  649
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signal transduction (Latz et al., 2007). Proteolysis may be re-
quired for this conformational shift in dimer structure. Alter-
natively, receptor cleavage may lead to altered affinity for 
ligand, which could also increase the likelihood of receptor 
activation. Although proteolysis seems to be an important 
requirement for all nucleic acid–sensing TLRs, whether 
the mechanisms that dictate this requirement are similar be-
tween TLR family members is not yet clear. Future studies 
focusing on the structural significance of receptor proteol-
ysis and how this event contributes to the orchestration of li-
gand binding, dimerization, and functional nucleic acid sensing 
will be of great value.
Finally, it is not obvious why so many proteases are able 
to process TLR9. The experiments presented in this paper 
indicate that the use of AEP and cathepsins is largely con-
served across cell types, although the role that these proteases 
play is not entirely overlapping. One possible explanation for 
the observed redundancy is that the region subject to prote-
olysis is unstructured and easily accessible. The ectodomains 
of TLR9, TLR7, and TLR3 all contain inserts or noncon-
served regions between LRRs. For example, TLR9 contains 
a large nonconserved loop between LRR14 and LRR15 that 
is susceptible to cathepsin-mediated proteolysis and contains 
at least two potential AEP consensus sites (Park et al., 2008; 
Sepulveda et al., 2009). It may be that the initial site of pro-
teolysis is not particularly important for receptor function. 
Instead, any cleavage event within the unstructured loop may 
be sufficient to allow cathepsins to trim the receptor to an 
optimal size for signaling. This mechanism could also allow 
for increased complexity in the number of proteases able to 
make the initial cut in TLR9.
Allowing flexibility in the types of proteases that can cleave 
the receptor has several perceivable advantages. Such flexibil-
ity may ensure that TLR9 can be activated across cell types 
expressing different protease repertoires or may allow the re-
ceptor to be activated throughout the endosomal system as the 
pool of active proteases changes. For example, it has been 
proposed that differential cytokine production in response to 
TLR9 ligands is compartment specific; activation from one 
class of endosome leads to type I interferon production, whereas 
activation in a distinct pool of endosomes results in a proin-
flammatory signature (Honda et al., 2005; Guiducci et al., 
2006; Sasai et al., 2010). Whether the proteolytic constituents 
of these compartments play a role in establishing these differ-
ences or other instances of differential signaling is an interest-
ing possibility that requires further attention.
MATERIALS AND METHODS
Reagents. All chemicals and reagents, unless noted otherwise, were pur-
chased from Thermo Fisher Scientific. Anti-HA (Clone 3F10) matrix was 
purchased from Roche. CpG oligonucleotides (TCCATGACGTTCCT-
GACGTT) with phosphorothioate linkages were purchased from Invitro-
gen. LPS, R848, and P(I:C) were purchased from InvivoGen. All antibodies 
for flow cytometry and ELISAs were purchased from eBioscience. Anti-HA 
(Roche) and goat anti–rat HRP (GE Healthcare) antibodies were used for 
immunoblotting. DMSO, z-FA-FMK, baflomycinA1, pepstatin A, and leu-
peptin (Sigma-Aldrich); ctsL inhibitor I (Z-Phe-Phe-CH2F), ctsB inhibitor 
(Fig. 5 A and Fig. S6). Treatment with LI-1 alone had little 
effect on TLR7 or TLR3 responses.
To examine TLR7 and TLR3 processing directly, we 
generated RAW cells stably expressing TLR7 or TLR3 bearing 
C-terminal HA tags. A cleaved form of each receptor was 
detectable by immunoblot (Fig. 5, B and C). Moreover, the 
sensitivity of the N-linked glycans to endoglycosidase H (Endo 
H) and PNGase is consistent with TLR3 and TLR7 trafficking 
similarly to TLR9. Full-length TLR7 and full-length TLR3 
were Endo H sensitive, indicating that these forms of the pro-
teins were localized in the ER (Fig. 5, B and C). In contrast, 
the cleaved forms of TLR7 and TLR3 were mostly Endo H 
resistant when compared with treatment with PNGase, indi-
cating that they have trafficked through the Golgi en route to 
the endolysosome (Fig. 5, B and C). In sum, these data sug-
gest that TLR7 and TLR3 are proteolytically processed in a 
manner similar to that of TLR9. Furthermore, proteolysis is 
required for the optimal signaling of these receptors.
In previous work, we put forth the hypothesis that pro-
teolytic processing is required to limit TLR9 activation to the 
endolysosomal compartments where nucleic acids are more 
likely to be foreign in origin than host derived (Ewald et al., 
2008). Sequence comparison of known vertebrate TLRs 
reveals that TLR7, TLR8, and TLR9 represent a family of 
closely  related  TLRs  that  appear  to  have  bifurcated  from 
other TLRs on a branch that also includes the TLR3 family 
(Roach et al., 2005). The findings presented in this paper 
suggest that receptor proteolysis is a regulatory mechanism 
that may have evolved alongside the ability to recognize nu-
cleic acids as a signature of infection.
Based on the accepted role that TLR7 and TLR9 play in 
contributing to lupus, arthritis, and psoriasis, it is reasonable 
that these receptors would be regulated in a similar manner. 
However, the finding that TLR3 is proteolytically processed, 
and that processing is required for an optimal response to 
poly(I:C), is rather surprising as activation of TLR3 by self-
nucleic acids has not been implicated in any autoimmune 
diseases. Structural studies of the TLR3 ectodomain bound 
to poly(I:C) indicate that a C-terminal cleavage product of 
TLR3 would contain residues implicated in direct interac-
tion between the two TLR3 molecules within the dimer as 
well as the lateral face (leucine-rich repeat [LRR] 19–LRR21) 
required for ligand binding (Bell et al., 2006; Liu et al., 2008). 
However, a putative ligand-binding site composed of basic 
residues within LRR1 and LRR3 would be removed upon 
proteolysis (Bell et al., 2006; Liu et al., 2008; Botos et al., 
2009). Interestingly, mutational analysis of the TLR9 N termi-
nus indicates that an analogous positively charged region may 
also be required for receptor activation (Peter et al., 2009). It 
certainly remains possible that the N terminus plays an impor-
tant role in the biology of these receptors before cleavage.
It is still unclear precisely how receptor proteolysis per-
mits TLR activation. A study using fluorescently labeled TLR9 
molecules to monitor protein interactions suggests that ligand 
binding by the TLR9 dimer induces a conformational change 
that brings the TIR domains in close proximity, enabling 650 Processing of nucleic acid–sensing TLRs | Ewald et al.
DCs were stained with anti-CD11b (M1/70), anti-CD11c (N418), anti-
TNF (MP6-XT22; all obtained from eBioscience), and anti-CD16/CD32 
antibody (2.4G2; University of California, San Francisco Monoclonal Anti-
body Core) as indicated.
AEP  knockdown  and  quantitative  real-time  RT-PCR. Sense and   
antisense oligonucleotides targeting AEP (sense sequence: 5-CCGAGAT-
CATGTCTTCATTTAC-3) were cloned into the LMP retroviral vector 
(Thermo  Fisher  Scientific)  according  to  the  manufacturer’s  instructions. 
Cells were carried in 4 µg/ml puromycin. Constructs were introduced into 
RAW cells or DC2.4 cells by retroviral transduction and knockdown was 
assessed by quantitative real-time RT-PCR. In brief, RNA was isolated 
using TRIzol plus RNA Purification System (Invitrogen). Gene-specific 
transcript levels were normalized to RPS17 mRNA. The following primers 
were used: AEP, 5-GGAAGCTGCTGAGAACCAAC-3 and 5-TGTG-
AGCATGGTCCTCTCTG-3;  RPS17,  5-CGCCATTATCCCCAG-
CAAG-3 and 5-TGTCGGGATCCACCTCAATG-3.
Online supplemental material. Fig. S1 shows deglycosylated TLR9 after 
treatment with protease inhibitors. Figs. S2–S4 and S6 show representative 
FACS plots for bar graphs depicted in Figs. 1–2 and 4–5, respectively. 
Fig. S5 shows representative signaling data for the AEP knockdown DC2.4 
cells described in Fig. 5. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20100682/DC1.
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